965 related articles for article (PubMed ID: 27920512)
1. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
[TBL] [Abstract][Full Text] [Related]
3. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of early medication use for COPD: a population-based cohort study.
Falk J; Dik N; Bugden S
Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
6. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
Bloom CI; Elkin SL; Quint JK
Int J Chron Obstruct Pulmon Dis; 2019; 14():279-287. PubMed ID: 30774325
[TBL] [Abstract][Full Text] [Related]
7. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
Bengtson LGS; DePietro M; McPheeters J; Fox KM
Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
[TBL] [Abstract][Full Text] [Related]
10. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
[TBL] [Abstract][Full Text] [Related]
11. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
Tsai YH; Yang TM; Lin CM; Huang SY; Wen YW
Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
[TBL] [Abstract][Full Text] [Related]
12. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
[TBL] [Abstract][Full Text] [Related]
13. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Punekar YS; Landis SH; Wurst K; Le H
Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
[TBL] [Abstract][Full Text] [Related]
14. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
[TBL] [Abstract][Full Text] [Related]
15. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.
Wurst KE; Shukla A; Muellerova H; Davis KJ
COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236
[TBL] [Abstract][Full Text] [Related]
16. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.
Ding B; Small M; Holmgren U
Int J Chron Obstruct Pulmon Dis; 2017; 12():1527-1537. PubMed ID: 28579771
[TBL] [Abstract][Full Text] [Related]
17. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
Ding B; Small M
Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
[TBL] [Abstract][Full Text] [Related]
18. Inhaled treatment of COPD: a Delphi consensus statement.
Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD.
Strange C; Walker V; DePietro M; Tong J; Kurlander J; Carlyle M; Millette LA; Wittbrodt E
Int J Chron Obstruct Pulmon Dis; 2019; 14():1377-1388. PubMed ID: 31303751
[No Abstract] [Full Text] [Related]
20. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
